ROBERT MASS, MD
Osteopathic Medicine at Elinor Ave, Mill Valley, CA
License number
California G50060
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
106 Elinor Ave, Mill Valley, CA 94941
Phone
(415) 497-2225
Professional information
Detection Of Erbb2 Gene Amplification To Increase The Likelihood Of The Effectiveness Of Erbb2 Antibody Breast Cancer Therapy
US Patent:
7993834, Aug 9, 2011
Filed:
Nov 19, 2007
Appl. No.:
11/942449
Inventors:
Robert D. Mass - Mill Valley CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 723
Abstract:
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells ErbB has been found to be amplified e. g. , by fluorescent in situ hybridization. ErbB antagonists described include an anti-HER2 antibody. Pharmaceutical packaging for providing the components for such treatment is also provided.
Treatment With Anti-Vegf Antibodies
US Patent:
2008024, Oct 9, 2008
Filed:
Jun 13, 2008
Appl. No.:
12/139186
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 35/02
US Classification:
4241451
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Treatment With Anti-Vegf Antibodies
US Patent:
2008029, Nov 27, 2008
Filed:
Jul 15, 2008
Appl. No.:
12/173764
Inventors:
GWENDOLYN FYFE - SAN FRANCISCO CA, US
ERIC HOLMGREN - PALO ALTO CA, US
ROBERT D. MASS - MILL VALLEY CA, US
WILLIAM NOVOTNY - FOSTER CITY CA, US
ERIC HOLMGREN - PALO ALTO CA, US
ROBERT D. MASS - MILL VALLEY CA, US
WILLIAM NOVOTNY - FOSTER CITY CA, US
Assignee:
GENENTECH, INC. - SOUTH SAN FRANCISCO CA
International Classification:
A61K 39/395, A61P 31/00
US Classification:
4241381
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Treatment With Anti-Vegf Antibodies
US Patent:
2008029, Nov 27, 2008
Filed:
Jul 25, 2008
Appl. No.:
12/180249
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 31/00
US Classification:
4241381
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Treatment With Anti-Vegf Antibodies
US Patent:
2009001, Jan 8, 2009
Filed:
Jul 25, 2008
Appl. No.:
12/179929
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 35/00, A61K 38/21
US Classification:
424 854, 4241451
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Vegf-Specific Antagonists For Adjuvant And Neoadjuvant Therapy And The Treatment Of Early Stage Tumors
US Patent:
2011005, Mar 3, 2011
Filed:
Jun 29, 2010
Appl. No.:
12/826001
Inventors:
NAPOLEONE FERRARA - SAN FRANCISCO CA, US
NINA KORSISAARI - JAMAICA PLAIN MA, US
ROBERT D. MASS - MILL VALLEY CA, US
NINA KORSISAARI - JAMAICA PLAIN MA, US
ROBERT D. MASS - MILL VALLEY CA, US
Assignee:
GENENTECH, INC. - SOUTH SAN FRANCISCO CA
International Classification:
A61K 39/395, A61K 31/7088, A61K 31/713, A61K 39/00, A61P 35/00
US Classification:
4241331, 514 44 R, 514 44 A, 4241581, 4241981, 4241451
Abstract:
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
Treatment With Anti-Vegf Antibodies
US Patent:
2011012, May 26, 2011
Filed:
Feb 2, 2011
Appl. No.:
13/019414
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Eric Holmgren - Palo Alto CA, US
Robert D. Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 38/21, A61P 35/00
US Classification:
424 854, 4241581, 4241331
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Gene Detection Assay For Improving The Likelihood Of An Effective Response To A Her2 Antibody Cancer Therapy
US Patent:
8440402, May 14, 2013
Filed:
Dec 12, 2011
Appl. No.:
13/323322
Inventors:
Robert D. Mass - Mill Valley CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 61, 435 723
Abstract:
The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e. g. , by fluorescent in situ hybridization.
Treatment With Anti-Vegf Antibodies
US Patent:
2007003, Feb 15, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/537553
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
Eric Holmgren - Palo Alto CA, US
Robert Mass - Mill Valley CA, US
William Novotny - Foster City CA, US
International Classification:
A61K 39/395, A61K 38/21, A61K 31/7048, A61K 31/522, A61K 31/513, A61K 31/573, A61K 31/4745, A61K 31/557
US Classification:
424145100, 424649000, 514492000, 514283000, 424085400, 514171000, 514263310, 514269000, 514251000, 514027000, 514573000
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Treatment With Anti-Vegf Antibodies
US Patent:
2007014, Jun 28, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/537542
Inventors:
Gwendolyn Fyfe - San Francisco CA, US
Eric Holmgren - Palo Alto CA, US
Robert Mass - Mill Valley CA, US
William Novotny - Foster City NY, US
Eric Holmgren - Palo Alto CA, US
Robert Mass - Mill Valley CA, US
William Novotny - Foster City NY, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 31/7072, A61K 31/4745, A61K 31/282, A61K 31/337, A61K 33/24
US Classification:
424155100, 424649000, 514049000, 514283000, 514492000, 514449000
Abstract:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.